Jeito Capital leads oversubscribed $92 million Series C financing round in Pulmocide finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Therini Bio Secures $17 Million Investment to Advance Fibrin Therapeutic Candidates Towards the Clinic
Strengthens investor syndicate with SV s Impact Medicine Fund, MRL Ventures and Sanofi Ventures joining to accelerate development of disease-modifying drugs for dementia and other inflammatory conditions.
News provided by
Share this article
Share this article
SOUTH SAN FRANCISCO, Calif, May 10, 2021 /PRNewswire/ Therini Bio, Inc. announced it has completed an oversubscribed Seed Extension round of financing. The capital will accelerate the development of Therini s lead program – a monoclonal antibody against fibrin – towards the clinic for patients with inflammatory conditions associated with vascular damage.
Therini Bio was co-founded by Dr. Katerina Akassoglou, PhD, based upon discoveries from her laboratory at Gladstone Institutes and also UC San Francisco that a cryptic epitope on fibrin, a blood-clotting factor, drives toxic chronic inflammation in the brain and t
Operator
Good morning, and welcome to the Iveric Bio first-quarter 2021 earnings conference call. [Operator instructions] Please note this call is being recorded. I would now like to turn the conference over to Kathy Galante, senior vice president, investor relations. Please go ahead.
Kathy Galante
Senior Vice President, Investor Relations
Good morning, and welcome to Iveric Bio s conference call. Representing Iveric Bio today are Glenn Sblendorio, chief executive officer; Pravin Dugel, president; David Carroll, chief financial officer; Dhaval Desai, chief development officer; Abraham Scaria, chief scientific officer; and Keith Westby, chief operating officer. I would like to remind you that today, we will be making statements relating to Iveric Bio s future expectations regarding operational, financial and research and development matters, including statements regarding our expectations for patient enrollment and patient retention in GATHER2, our second Phase 3 clinical trial
BOSTON and LONDON, May 5, 2021 /PRNewswire/ The Dementia Discovery Fund (DDF), the venture capital fund investing in, and creating, biotech companies pursuing transformational therapeutic
Cumulus Neuroscience Announces £6 million Funding Round Led by the Dementia Discovery Fund and joined by LifeArc and UK Future Fund
- Proceeds to be used to advance next-generation integrated physiological and digital biomarker platform that provides clinical trial data and AI-powered insights, to accelerate the development of life-changing CNS therapies
- Platform addresses the significant unmet need for faster, more robust, and cost-effective execution and evaluation of neuroscience clinical trials, in a real-world setting
- Platform has been designed by industry to provide a gold standard measurement of disease progression and treatment response for new CNS therapeutics
News provided by